ロード中...
Phase I Study of Pasireotide (SOM 230) and Everolimus (RAD001) in Advanced Neuroendocrine Tumors
Octreotide and everolimus have demonstrated efficacy in neuroendocrine tumors. Pasireotide is a somatostatin analog with binding affinity to a broader range of somatostatin receptor subtypes than octreotide. We performed a phase I study to evaluate the safety and feasibility of combining pasireotide...
保存先:
| 出版年: | Endocr Relat Cancer |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4469068/ https://ncbi.nlm.nih.gov/pubmed/22736724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-11-0382 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|